Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
CGD Policy Blogs
In January 2021, India embarked on one of the world’s largest vaccination drives ever in an attempt to control COVID-19 in the country. After nine months, 29 percent of the national population is partially vaccinated, and only 15 percent is fully vaccinated.
Before Recommending the RTS,S Malaria Vaccine for Wider Use, WHO Should Address Three Key Considerations
Last month, the world woke up to promising news on malaria prevention: administering an existing malaria vaccine (RTS,S) in addition to antimalarial drugs before the rainy season reduced child hospitalizations and deaths by approximately 70 percent in Burkina Faso and Mali. These results arrived ahead of a forthcoming decision from the World Health Organization on whether to recommend RTS,S for broader use. This blog argues that WHO should consider value for money and address three key considerations before making their reccomendation.
Getting the Best We Can Buy: Three Solutions to Improve the Use of Value for Money Evidence in Global Development
The need for effective evidence-informed priority-setting in global development is more urgent than ever, with widespread global challenges and reduced funding due to both COVID-19 related public spending and economic slowdowns. This blog explores three key barriers to using value for money evidence in global development and offers three solutions to overcome these challenges.
The online platform C19economics was created to support researchers and decision makers by collating the health economic literature published on the COVID-19 pandemic into an easily searchable repository. After reviewing the literature, we found three notable gaps in coverage in terms of geographical focus and topic areas.
LAC Countries are Struggling to Deliver COVID-19 Vaccinations—Six Actions Are Needed to Turn the Tide
Historically, the Americas have been the world leader in routine vaccination, vaccine introduction, and implementation of mass vaccination campaigns against infectious diseases. It was the first region to eliminate rubella and measles, eradicate smallpox, and be declared polio-free.
Better Together: Exploring the Role of Pooled Procurement in Improving Access to Medicines amid COVID-19
Access to safe, effective, and affordable essential medicines is an integral global health goal, and all the more important during a public health emergency like COVID-19. Supply chain inefficiencies, procurement capacity constraints, and financial difficulties impede access to affordable, quality medicines; crises exacerbate these issues.
Vaccines have become a central instrument of our long-term response to the pandemic. Vaccination campaigns have now started around the world and will confer significant direct protection against infection, severe illness, and death to those inoculated. It may also protect against transmission, though robust evidence is yet to be confirmed.
A lot of recent discussions focus on how to expand COVID-19 vaccine manufacturing capacity in low- and middle-income countries (LMICs). The conversations highlight the importance of technology transfer and the capability of the tech transfer receiving sites (the facilities in these countries that would then produce vaccines locally), including having specialized equipment and personnel.